(Q39600616)

13 September 2017

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling (English)

1 reference

13 September 2017

1 reference

5

1 reference

13 September 2017

C Garofalo

1

0 references

Piero Picci

object named as

P Picci

11

0 references

Annalisa Astolfi

6

object named as

A Astolfi

1 reference

13 September 2017

M C Manara

2

1 reference

13 September 2017

G Nicoletti

3

1 reference

13 September 2017

M T Marino

4

1 reference

13 September 2017

G Pandini

7

1 reference

13 September 2017

J A López-Guerrero

8

1 reference

13 September 2017

K-L Schaefer

9

1 reference

13 September 2017

A Belfiore

10

1 reference

13 September 2017

K Scotlandi

12

1 reference

13 September 2017

language of work or name

English

0 references

publication date

31 January 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

2730-2740

1 reference

13 September 2017

24

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.640

13 September 2017

0 references

cites work

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Redundancy of autocrine loops in human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

The type 1 insulin-like growth factor receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

A monoclonal anti-peptide antibody reacting with the insulin receptor β-subunit. Characterization of the antibody and its epitope and use in immunoaffinity purification of intact receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

NVP-BEZ235 as a new therapeutic option for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Targeting insulin-like growth factor 1 receptor in sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

Analysis of insulin signalling by RNAi-based gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.640

21 January 2018

Identifiers

DOI

10.1038/ONC.2010.640

1 reference

Dimensions Publication ID

13 September 2017

1007760714

0 references

Fatcat ID

release_drk4j6b2hzc73e3jecynue5qpm

0 references

1 reference